Sanofi Selects Recursion Immunology Drug Candidate for Development
Bitget2026/10/15 12:46- Sanofi has optioned the first development candidate from its research collaboration with Recursion, adding it to its development pipeline.
- The potential first-in-class oral small molecule, developed using AI-enabled design, targets a challenging pair of targets implicated in inflammatory disease.
- Phase 1 trials are expected in 2027, with Sanofi funding and leading further development and commercialization.
- The option triggered a $10 million milestone payment, bringing total upfront and milestone payments under the collaboration to $144 million.
- Recursion remains eligible for more than $300 million in additional program milestones, with average low-double-digit royalties on net sales if successfully commercialized.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
